Adapter AC 40W Charger AS1 EXA0901XH 1015 1001PX 1001P 1001HA PC Eee ASUS Power Other Business & Industrial


  1. Home
  2. Adapter AC 40W Charger AS1 EXA0901XH 1015 1001PX 1001P 1001HA PC Eee ASUS Power
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
40W AC Adapter Charger Power ASUS Eee PC 1001HA 1001P 1001PX 1015 EXA0901XH AS1
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Output Voltage(s): 19V
Compatible Product Line: Asus Eee PC Max. Output Power: 40W
Compatible Model: 19V 2.1A (Tip 2.5*0.7mm) Output Current: 2.1A
Mains Lead: Not Included, Sells Separately If Required Manufacturer warranty: 1 year
Shipping Time: Before 2pm Same Day Adapter Pin: 2.5mm X 0.7mm
MPN:

EXA1004EH, FSP040-RAC

Country/Region of Manufacture: China
Brand:

Lite-am

Unit Quantity: 1
Packing: Safe Secure Packaging Compatible Asus PN: 04G26B001010, 04G26B001020




published on tue nov 09 2021

Adapter AC 40W Charger AS1 EXA0901XH 1015 1001PX 1001P 1001HA PC Eee ASUS Power Other Business & Industrial

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Adapter AC 40W Charger AS1 EXA0901XH 1015 1001PX 1001P 1001HA PC Eee ASUS Power Other Business & Industrial

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS